DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals (NYSE MKT:NAVB) reports financial results for the quarter ending September 30, 2015. The Company achieved the following financial highlights:
•Third quarter 2015 total revenue of $4 million; comprised of $3 million in Lymphoseek® (technetium Tc 99m tilmanocept) injection sales, $550,000 in Lymphoseek license revenue, and $477,000 in grant and other revenue
Help employers find you! Check out all the jobs and post your resume.
